SBIR/STTR Research Award

Innovations to expand and accelerate the commercial impact of DNA modifications

Award identifier f66f5fd1c948aa2852064f431c188fe3f12b7f109ddaf27cf30c905c3413c2e1Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$399,538

Program and phase

STTR · Phase I

Award year

2024

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
DNAli Data Technologies, Inc.
Proposal award date
2024-06-15
Contract end date
2025-05-31
UEI
D1GNGHBC83Q6
Solicitation number
PA23-232
Topic code
NHGRI

Research abstract

PROJECT SUMMARY Chemical modifications to synthetic DNA are of central importance to both: 1) understanding biology and disease and 2) enabling a wide range of biomedical applications and research tools. However, despite their importance, most modification patterns are not possible to make and those that are are exorbitantly expensive to synthesize (by at least 10x), in contrast to the rapidly dropping costs for unmodified DNA synthesis. The central challenge is that the most advanced methods to create modified DNA oligos continue to rely on phosphoramidite synthesis, an organic chemistry process that uses harsh reaction conditions that require expensive chemically protected monomers and associated deprotection steps, or that simply prohibits certain types of modified DNAs from being synthesized at all. To address this challenge, we have developed a robust platform technology capable of pro- ducing chemically modified DNA. It is technologically differentiated from the current state of the art through its use of sustainable enzymatic synthesis in mild and low temperature conditions, compatibility with a diverse range of modification types, and low cost and recycleable templates and reagents. The proposed work seeks to ad- vance the commercial potential of this technology by: Aim I – creating modified DNA products that cannot be ordered from any existing vendor; Aim II – developing an innovation on our technology that will eliminate the most costly reagent in our synthesis process, the biotinylated template; and Aim III – establishing and mapping the breadth of modifications that our platform technology can incorporate into DNA oligos and their relative syn- thesis efficiencies.

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.